Our Pipeline

Anebulo at a Glance

We are a clinical stage biotech company developing novel solutions to help people suffering from addiction. Our lead product candidate is an antidote to treat cannabinoid intoxication.

ANEB-001 Cannibinoid Intoxication

Phase 2

Anebulo aims to leverage distinct formulations/combinations of the same API to develop 3 distinct products to help patients suffering from addiction. This will allow the company to rapidly advance to proof of concept trials.

ANEB-001PHASE 2

ANEB-001 is being developed with the intent to quickly and effectively reverse the negative effects of cannabinoid intoxication within one hour of administration. ANEB-001is a competitive CB1 antagonist with a high affinity for the human CB1 receptor. There is currently no medical treatment approved to alleviate the symptoms of cannabinoid intoxication.

ANEB-001 is a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for cannabinoid intoxication. We believe ANEB-001 will reverse the symptoms of cannabinoid intoxication within 1 hour of administration based on our Phase 1a and 1b data.